“Top Stories” from SABCS 2022

At the end of the San Antonio breast cancer symposium, Belgian experts were asked to compile a top three of the most important presentations.

Unanimously chosen was the POSITIVE study, which showed that it is safe to temporarily interrupt adjuvant endocrine treatment in pregnancy.

The DESTINY Breast02 study was also in the top 3. The study demonstrated superior efficacy for trastuzumab deruxtecan in metastatic HER2+ breast cancer after one or more lines of anti-HER2 therapy.

A third top story was the MonarchE study where adding the CDK4/6 inhibitor abemaciclib to standard adjuvant endocrine treatment resulted in a significant improvement in invasive disease-free survival….

We’ll let you hear another report from our experts on the ground.